Half-Year 2022 Financial and Clinical Trials Update
PRED oncology development programs -1
Molecule
Indication
Solid tumors
Phase
# of patients
Status
Oncology
~150
FPI Q2 2018
Data presented at ESMO 2020
Recruitment completed Q2 2021
Roche
CT Identifier
FAP-4-1BBL (RG7827)
3L+ MSS MCRC
FPI Q3 2021
lb
80
NCT04826003
Combination study with cibisatamab
Part I: FPI Q3 2019
CD19-4-1BBL (RG6076)
R/R B cell non-Hodgkin's lymphoma
362
NCT04077723
Part II: FPI Q3 2020
Part I: FPI Q2 2020; recruitment completed Q4
PD1-IL2v (RG6279)
Solid tumors
348
2021
NCT04303858
Part II: FPI Q1 2022
FPI Q4 2014
la
149
NCT02324257
Data presented at ASCO 2017
cibisatamab
(CEA x CD3, RG7802)
CEA-positive solid tumors
FPI Q1 2016
lb
228
NCT02650713
Data presented at ASCO 2017
3L+ MSS MCRC
Solid tumors
PD1-LAG3 (RG6139)
Solid tumors
lb
46
FPI Q1 2019
NCT03866239
|
320
FPI Q4 2019
NCT04140500
||
=
210
FPI Q2 2021
Randomized trial, compared with nivolumab
NCT04785820
TALIOS
150View entire presentation